Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
- Participants will receive capecitabine orally twice daily for 14 days, from the evening
of Day 1 to the morning of Day 15 of the study, and oxaliplatin on Day 1 of each cycle
(one cycle is 3 weeks long) until their cancer worsens or they experience any serious
- Participants will undergo the following procedures midcycle (between Days 10 and 14 of
each cycle): Symptom and side effect assessment and blood samples.
- After every two cycles of study treatment, participants will undergo a CT or MRI scan
to measure the tumor.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the response rate to capecitabine and oxaliplatin in patients with locally advanced or metastatic pancreatic adenocarcinoma
Rebecca Miksad, MD, MPH
Beth Israel Deaconess Medical Center
United States: Institutional Review Board
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|